{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the Supplementary Information section of this notice to Capstan Therapeutics, Inc. (Capstan), a company located in San Diego, California, the United States of America.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2025/07/03/2025-12409.html","cfr_references":[],"citation":"90 FR 29571","comment_url":null,"comments_close_on":"2025-07-18","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 18, 2025 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2025-12409","effective_on":null,"end_page":29572,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2025/07/03/2025-12409.xml","html_url":"https://www.federalregister.gov/documents/2025/07/03/2025-12409/prospective-grant-of-an-exclusive-patent-license-the-development-of-an-in-vivo-anti-cd19-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2025-12409?publication_date=2025-07-03","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2025-07-03/2025-12409/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":318,"last_updated":"2026-08-26 12:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-07-03/pdf/2025-12409.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-12409.pdf?1751460309","publication_date":"2025-07-03","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2025/07/03/2025-12409.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2025-07-03T08:11:10Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":29571,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases","toc_doc":"Exclusive Patent; The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":90}